please answer the second question. the firs one is potency. i added it for the numbers sake

thats all the information that is provided

Genenco is developing a new drug that will slow the aging process. In order to succeed, two breakthroughs are needed, one to increase the potency of the drug, and the second to eliminate toxic side effects. Research to improve the drug's potency is expected to require an upfront investment of $10 and take 2 years; the drug has a 5% chance of success. Reducing the drug's toxicity will require a $7 up-front investment, take 5 years, and has a 15% chance of success. If both efforts are successful, Genenco can sell the patent for the drug to a major drug company for $3000. Use a 6% discount rate. Which research project should Genenco do first? Toxicity O Potency O Doesn't matter Same numbers as Q9 except where noted. Genenco is developing a new drug that will slow the aging process. In order to succeed, two breakthroughs are needed, one to increase the potency of the drug, and the second to eliminate toxic side effects. Research to improve the drug's potency is expected to require an upfront investment of $13.2 and take 2 years [the cost of potency may not be the same as in Q9]; the drug has a 5% chance of success. Reducing the drug's toxicity will require a $7 up-front investment, take 5 years, and has a 15% chance of success. If both efforts are successful, Genenco can sell the patent for the drug to a major drug company for $3000. Use a 6% discount rate. What is the overall NPV if Genenco does the potency research first? Remember that if potency fails then Genenco will not do the toxicity research. Round your answer to the nearest $0.01